Oxigene files $75 million shelf

New York, Sept. 23 - Oxigene, Inc. registered a $75 million shelf in an S-3 filing with the Securities and Exchange Commission.

Included in the shelf are common stock, debt securities and warrants. The debt may be structured as convertibles, and the securities may be sold in combination as units.

As part of the total, Oxigene is carrying forward $10.79 million of securities previously registered but unsold.

The Waltham, Mass., biopharmaceutical company will use proceeds for general corporate purposes.

Oxigene is developing small-molecule therapeutics to treat cancer and eye diseases, specifically drugs that selectively disrupt newly formed abnormal blood vessels associated with solid tumor progression and visual impairment.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.